Avandia (rosiglitazone): Ongoing Review of Cardiovascular Safety
Links shared publicly online about this topic.
- 1,362total visits
Avandia (rosiglitazone): Ongoing Review of Cardiovascular Safety
fda.gov —
View full resource at fda.gov
Tags: Diabetes Type 2 Medication, Diabetes Medication, FDA, Avandia, Avandamet, Avandaryl
Most Recently Shared on February 22, 2010 at 9:42 pm By:
RT @bobbyjae avandia (rosiglitazone) ongoing review of cardiovascular safety http://bit.ly/8Z3ccl #Pharma #FDA #biotech #bigPharma #medicine
Also Shared By:
CHMP Meets To Discuss Avandia And Pandemrix, Europe - QualityPoint Technologies
qualitypointtech.net — “The Committee for Medicinal Products for Human Use (CHMP) met on Wednesday 8 September to discuss the ongoing benefit-risk review of the rosiglitazone-containing medicines Avandia, Avandamet and Avaglim. The Committee discussed all of the available data on the risk of cardiovascular problems associated with rosiglitazone in order to prepare for its next scheduled meeting of 20-23 September 2010, when it expects to finalise its review. The CHMP identified a number of further questions that it is ” View full resource at qualitypointtech.net
Most Recently Shared on September 9, 2010 at 2:09 pm By:
CHMP Meets To Discuss Avandia And Pandemrix, Europe: The Committee for Medicinal Products for Human Use (CHMP) met... http://bit.ly/bKsMhe
CHMP Meets To Discuss Avandia And Pandemrix, Europe
medicalnewstoday.com — “The Committee for Medicinal Products for Human Use (CHMP) met on Wednesday 8 September to discuss the ongoing benefit-risk review of the rosiglitazone-containing medicines Avandia, Avandamet and A” View full resource at medicalnewstoday.com
Most Recently Shared on September 9, 2010 at 1:26 pm By:
MedicalNewsToday: CHMP Meets To Discuss Avandia And Pandemrix, Europe http://bit.ly/d3sOPJ Full http://bit.ly/agmp1v
European Medicines Agency Update On Ongoing Benefit-Risk Review Of Avandia, Avandamet And Avaglim
medicalnewstoday.com — “The European Medicines Agency is currently reviewing rosiglitazone to determine the impact of new data, from recent publications on the risk of cardiovascular problems, on the benefit- risk profil” View full resource at medicalnewstoday.com
Most Recently Shared on July 23, 2010 at 3:06 pm By:
MNT Cardiovascular Health News
European Medicines Agency Update On Ongoing Benefit-Risk Review Of Avandia, Avandamet And Avaglim http://mnt.to/3GtX #cardiovascular
FDA reviews cardiovascular safety of Avandia - MPR
empr.com — “The FDA has notified healthcare professionals and patients that it is reviewing the primary clinical trial data from the long-term RECORD study to evaluate the cardiovascular safety of Avandia (rosiglitazone tablets, from GlaxoSmithKline).” View full resource at empr.com
Most Recently Shared on March 1, 2010 at 2:32 pm By:
Physician Assistants Health News Feed
FDA reviewing primary clinical trial data to evaluate the cardiovascular safety of Avandia (rosiglitazone): http://bit.ly/a6w87B
FDA reviews cardiovascular safety of Avandia - MPR
empr.com — “The FDA has notified healthcare professionals and patients that it is reviewing the primary clinical trial data from the long-term RECORD study to evaluate the cardiovascular safety of Avandia (rosiglitazone tablets, from GlaxoSmithKline).” View full resource at empr.com
Most Recently Shared on February 23, 2010 at 4:26 pm By:
MPR News: FDA reviews cardiovascular safety of Avandia: The FDA has notified healthcare professionals and patients... http://bit.ly/bfuQqZ
FDA reviews cardiovascular safety of Avandia - ONA
oncologynurseadvisor.com — “The FDA has notified healthcare professionals and patients that it is reviewing the primary clinical trial data from the long-term RECORD study to evaluate the cardiovascular safety of Avandia (rosiglitazone tablets, from GlaxoSmithKline).” View full resource at oncologynurseadvisor.com
Most Recently Shared on February 23, 2010 at 4:06 pm By:
OncologyNurseAdvisor Medical Education, Medical Publisher, Oncology, and Nursing
FDA reviews cardiovascular safety of Avandia http://goo.gl/fb/JrKN
FDA Alert: Avandia (rosiglitazone): Ongoing Review of Cardiovascular Safety
drugs.com — “FDA Alert: Avandia (rosiglitazone): Ongoing Review of Cardiovascular Safety” View full resource at drugs.com
Most Recently Shared on February 22, 2010 at 9:47 pm By:
FDA Alert - Avandia (rosiglitazone): Ongoing Review of Cardiovascular Safety - http://bit.ly/bDhng0
Advertisement
eyeonfda
@eyeonfda
FDA issues MedWatch - Avandia (rosiglitazone): Ongoing Review of Cardiovascular Safety - http://ow.ly/1a4EB
1 year ago...